Bonesupport Holding AB Overview
Pro stress-test →Bonesupport Holding AB is an orthobiologics company that develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company leverages its proprietary CERAMENT platform to address critical gaps in orthopedic surgery, trauma care, and bone infection treatment, with products that remodel to host bone and can deliver antibiotics.
Strategic Profile
Pro stress-test →The company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing, with products focused on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. In 2024, Bonesupport Holding AB's revenue was 898.73 million SEK, an increase of 52.05% compared to the previous year.
Competitive Landscape
Pro stress-test →Bonesupport competes in the orthobiologics space against established surgical companies and specialized bone graft manufacturers. The company's CERAMENT platform represents a differentiated approach by combining biocompatibility with antibiotic delivery, reducing direct competition from traditional bone graft alternatives. Key competitors include Graftys and other regional orthobiologic players.
Industry Context
Bonesupport Holding AB operates in Orthobiologics / Regenerative Medicine / Medical Devices.
Key facts
Founded: 1999 · Headquarters: Lund, Sweden · Revenue: $110M (TTM as of Sep 2025); 898.73M SEK (2024) · Market cap: $2.04B